Multiple Sclerosis In Childhood: Contribution Of Serial Mri To Earlier Diagnosis

Background: The impact of new asymptomatic spinal cord lesions (a-SL) in multiple sclerosis (MS) course is poorly characterized. Objective: The objective of this research paper is to assess the prognostic value of a-SL in predicting MS course. Methods: Relapsing–remitting MS patients who received serial MRI (brain and spinal) at baseline (t1) and within 12 to 36 months (t2) during clinical stability, and had a follow-up (t2–t3) ⩾24 months were included. Relapses and disability progression were evaluated between t2 and t3. Results: Of 413 consecutive screened MS patients, 103 patients (65 females, median age 43 years) were included. After a median t1–t2 interval of 17 (IQR 13–26) months, 25.2% and 43.7% patients had ⩾1 new a-SL (a-SL+) and asymptomatic brain lesions (a-BL+), respectively. Relapse risk between t2 and t3 (median interval: 42 (IQR 32–57.5) months) was significantly increased in a-SL+ and/or a-BL+ vs a-BL– and a-SL– (HR = 2.31, 95% CI = 1.13–4.72, p = 0.02). No differences in the risk of disability progression were found in a-SL+ and/or a-BL+ vs a-SL- and a-BL–. Conclusion: a-SL occur in one-quarter of clinically stable RRMS, and combined with a-BL contribute significantly in predicting future disease course.

Download Full-text

Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans

Journal of Clinical Neuroscience ◽

10.1016/j.jocn.2005.02.017 ◽

2006 ◽

Vol 13 (2) ◽

pp. 282-284 ◽

Cited By ~ 18

Author(s):

Jeffrey P. Reiss ◽

Diana Sam ◽

Jitender Sareen

Keyword(s):

Multiple Sclerosis ◽

Temporal Lobe ◽

Left Temporal Lobe ◽

Mri Scans ◽

Temporal Lobe Lesions ◽

Serial Mri

Download Full-text

A controlled trial of plasma exchange in multiple sclerosis using serial MRI and multimodal evoked potentials as efficacy parameters

Journal of Neuroimmunology ◽

10.1016/0165-5728(95)99123-z ◽

1995 ◽

Vol 56-63 ◽

pp. 74-74

Author(s):

P.S. Sørensen ◽

H. Wanscher ◽

W. Szpirt ◽

C.V. Jensen ◽

M. Ravnborg ◽

...

Keyword(s):

Multiple Sclerosis ◽

Evoked Potentials ◽

Plasma Exchange ◽

Controlled Trial ◽

Multimodal Evoked Potentials ◽

Efficacy Parameters ◽

Serial Mri

Download Full-text

Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis

Neurology ◽

10.1212/wnl.0000000000012230 ◽

2021 ◽

pp. 10.1212/WNL.0000000000012230

Author(s):

Evan A. Jolliffe ◽

Yong Guo ◽

Todd A Hardy ◽

P. Pearse Morris ◽

Eoin P. Flanagan ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Course ◽

Tertiary Care ◽

Demyelinating Diseases ◽

Demyelinating Lesions ◽

Tertiary Care Centers ◽

Multiple Sclerosis Patients ◽

Serial Mri ◽

Distinct Subtype

Objective:To describe clinical, radiological and pathological features of patients with Baló’s concentric sclerosis (BCS) and assess overlap between BCS and other central nervous system inflammatory demyelinating diseases.Methods:Retrospective review of BCS cases from US and Australian tertiary care centers.Results:We identified 40 BCS cases with 38 available MRIs. Solitary MRI lesions were present in 26% (10/38). We saw >1 active concurrent BCS lesion in 45% (17/38). A third (13/38) had multiple sclerosis-suggestive lesions on the index MRI, of which 10 fulfilled Barkhof criteria. In patients with serial MRI performed within one month of the index MRI, lesions expanded radially with sequentially increased numbers of T2 hyperintense rings 52% (14/27). Initially non-enhancing or centrally enhancing lesions subsequently developed single or multiple enhancing rings (41%; 9/22) and incomplete enhancing rings (14%; 3/22). Discordance between rings as they appear on ADC, DWI, and gadolinium-enhanced imaging was observed in 67% (22/33). AQP4-IgG (n=26) and MOG-IgG (n=21) were negative in all patients with serum available. Clinical response to steroid treatment was seen in 46% (13/28). A monophasic clinical course was present in 56% (18/32) at last follow-up (median 27.5 months; range 3-100 months). The initial attack was fatal in 10% (4/40). Median time from symptom onset to death was 23 days (range 19-49 days). All 17 patients with pathology available demonstrated typical findings of multiple sclerosis. Patients with active demyelinating lesions all demonstrated oligodendrocytopathy (pattern III).Conclusions:BCS may be a distinct subtype of multiple sclerosis characterized by pattern III immunopathology.

Download Full-text